Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Mantosh Kumar Satapathy  | Taipei Medical University | Taiwan

Dr. Mantosh Kumar Satapathy, Ph.D., is a distinguished biomedical scientist, biotechnologist, pharmacologist, and tissue engineer based at Taipei Medical University, Taiwan, with extensive international experience in pharmacology, biomedical engineering, and nanobiotechnology. He earned his Ph.D. in Biomedical Materials and Tissue Engineering from Taipei Medical University, following an M.Tech. in Industrial Biotechnology and a Bachelor of Pharmacy, establishing a strong foundation in translational medical research. Dr. Satapathy has held postdoctoral and research fellow positions at leading institutions, leading projects on advanced nanodrug delivery systems, stem cell therapeutics, tissue engineering, and nanoformulation design, while supervising molecular biology laboratories and mentoring junior researchers. His research contributions include the development of stimuli-responsive nanocomposite hydrogels for orthopedic and skin tissue regeneration, engineering of nanocurcumin-based formulations for targeted therapies, and investigations into gene regulation and drug repurposing in cancer and skin pathologies. He has published extensively in high-impact peer-reviewed journals, contributed to international book chapters, co-invented a U.S. patent, and presented his work at global scientific conferences. Dr. Satapathy’s work has been recognized with multiple Outstanding Postdoctoral Researcher awards, and he actively serves as a peer reviewer, reflecting his leadership in the scientific community. He is a life member of professional organizations, has completed specialized research training in molecular diagnostics and biotechnology, and continues to advance interdisciplinary research that bridges fundamental science and clinical application, demonstrating exceptional impact in biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Banerjee, P., Satapathy, M., Mukhopahayay, A., & Das, P. (2014). Leaf extract mediated green synthesis of silver nanoparticles from widely available Indian plants: Synthesis, characterization, antimicrobial property and toxicity analysis. Bioresources and Bioprocessing, 1(1), 3.

2. Satapathy, M. K., Yen, T. L., Jan, J. S., Tang, R. D., Wang, J. Y., Taliyan, R., & Yang, C. H. (2021). Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB. Pharmaceutics, 13(8), 1183.

3. Satapathy, M. K., & Das, P. (2014). Optimization of crystal violet dye removal using novel soil-silver nanocomposite as nanoadsorbent using response surface methodology. Journal of Environmental Chemical Engineering, 2(1), 708–714.

4. Satapathy, M. K., Banerjee, P., & Das, P. (2015). Plant-mediated synthesis of silver-nanocomposite as novel effective azo dye adsorbent. Applied Nanoscience, 5(1), 1–9.

5. Satapathy, M. K., Nyambat, B., Chiang, C. W., Chen, C. H., Wong, P. C., Ho, P. H., … (2018). A gelatin hydrogel-containing nano-organic PEI–Ppy with a photothermal responsive effect for tissue engineering applications. Molecules, 23(6), 1256.

Laura Machin Galarza | Pharmacology | Young Scientist Award

Published on by World Top Scientists

Assist. Prof. Dr. Laura Machin Galarza | Pharmacology | Young Scientist Award

Laura Machin Galarza | University of Havana | Cuba

Dr. Laura Machin Galarza is an Assistant Professor and Researcher at the Institute of Pharmacy and Foods, University of Havana, specializing in pharmaceutical sciences and parasitology. She holds a Bachelor’s, Master’s, and Doctorate in Pharmaceutical Sciences from the University of Havana, where her academic journey has been marked by excellence and commitment to translational research. Dr. Machin has undertaken prestigious research stays at institutions in Austria, Germany, China, and Cuba, contributing to international collaborations focused on pharmacology, toxicology, and biopharmaceutical innovation. Her professional experience includes leadership in multidisciplinary projects exploring the antiprotozoal and antileishmanial potential of natural and synthetic compounds, advanced drug delivery systems, and pharmacological recycling strategies. She has authored multiple peer-reviewed publications in high-impact journals such as Pharmaceuticals, Molecules, and Experimental Parasitology, demonstrating expertise in medicinal chemistry and drug development. Dr. Machin’s work has been recognized through contributions to award-winning research honored by the Cuban Academy of Sciences. She actively serves in academic editorial processes, participates in professional scientific societies, and holds certifications that reflect her dedication to research excellence, innovation, and scientific leadership in the field of pharmaceutical sciences.

Profiles: Google Scholar | Scopus 

Featured Publications

1. B. Salehi, L. Machin, L. Monzote, J. Sharifi-Rad, S. M. Ezzat, M. A. Salem, et al., “Therapeutic potential of quercetin: new insights and perspectives for human health,” ACS Omega, vol. 5, no. 20, pp. 11849–11872, 2020.

2. B. Tamargo, L. Monzote, A. Piñón, L. Machín, M. García, R. Scull, W. N. Setzer, “In vitro and in vivo evaluation of essential oil from Artemisia absinthium L. formulated in nanocochleates against cutaneous leishmaniasis,” Medicines, vol. 4, no. 2, p. 38, 2017.

3. L. Machín, R. Nápoles, L. Gille, L. Monzote, “Leishmania amazonensis response to artemisinin and derivatives,” Parasitology International, vol. 80, p. 102218, 2021.

4. G. Geroldinger, M. Tonner, J. Quirgst, M. Walter, S. De Sarkar, L. Machín, et al., “Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: a possible link,” Biochemical Pharmacology, vol. 173, p. 113737, 2020.

5. L. Machín, B. Tamargo, A. Piñón, R. C. Atíes, R. Scull, W. N. Setzer, L. Monzote, “Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) essential oils formulated in nanocochleates against Leishmania amazonensis,” Molecules, vol. 24, no. 23, p. 4222, 2019.

Lixin Yan | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Mrs. Lixin Yan | Pharmacology | Best Researcher Award

Medical manager | Sinocelltech Ltd | China

Mrs. Lixin Yan is an accomplished medical manager with extensive experience in clinical research, specializing in oncology, infectious diseases, vaccines, and metabolic products. Over the years, she has led multiple Phase I–III clinical trials, contributing to protocol development, medical monitoring, feasibility assessment, and regulatory submissions. Her work has been instrumental in the clinical development of innovative therapies, including PD-1 inhibitors, EGFR-targeted treatments, HPV and COVID-19 vaccines, insulin, and GLP-1 products. She demonstrates strong expertise in GCP compliance, regulatory processes, and cross-functional team collaboration, ensuring high-quality research outcomes. Mrs. Yan has published impactful peer-reviewed articles, including first-author papers, highlighting her ability to generate reliable clinical evidence. Her dedication to advancing medical science through rigorous research and mentorship reflects her potential to lead future high-impact studies. Her measurable research impact is demonstrated through 68 citations, 5 documents, and an h-index of 4 according to Scopus.

Profile: Scopus

Featured Publications

1. L. Yan, J. Yi, D. Liu, J. Li, A. A. H. Baidoo, and L. Xie, “Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial,” Contemporary Clinical Trials Communications, 2025.

Ksenia Blinova | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Ksenia Blinova | Pharmacology | Best Researcher Award

Associate Director at US Food and Drug Administration, United States

Dr. Ksenia Blinova, Ph.D., is the Associate Director for the Division of Applied Regulatory Science at the U.S. Food and Drug Administration, where she leads innovative research, regulatory reviews, and scientific consultations that advance translational science in support of public health. With a strong academic foundation in physics, mathematics, and cardiac electrophysiology, she has built a distinguished career focused on bridging fundamental science with regulatory applications. Since joining the FDA as a Commissioner’s Fellow, Dr. Blinova has held key leadership roles, including Deputy Director of the Division of Biomedical Physics, where she led multidisciplinary teams in developing over forty regulatory science tools that improved the evaluation of medical devices across fields such as cardiology, neurostimulation, diagnostics, and patient monitoring. Her career reflects a unique combination of scientific excellence, leadership, and commitment to advancing safe and effective medical products, making her an influential figure in the field of regulatory science.

Professional Profile 

Scopus Profile | ORCID Profile 

Education

Dr. Ksenia Blinova earned her undergraduate and doctoral degrees in Physics and Mathematics from Moscow State University, where she developed a strong foundation in quantitative sciences and analytical problem-solving. She further advanced her academic journey through a postdoctoral fellowship at the National Heart, Lung, and Blood Institute at the National Institutes of Health. Her research during this period centered on cardiac electrophysiology and metabolism, areas that deepened her expertise in biomedical applications of physical sciences. This educational trajectory not only equipped her with advanced technical knowledge but also gave her a unique interdisciplinary perspective that integrates rigorous physics and mathematical methodologies with life sciences and clinical research. Her educational background has been pivotal in shaping her ability to address complex regulatory and scientific challenges, contributing to her capacity for innovation and leadership in translational science and regulatory policy at the intersection of medicine, technology, and public health.

Experience

Dr. Blinova has built a distinguished career at the U.S. Food and Drug Administration, beginning as a Commissioner’s Fellow and progressing to influential leadership roles. As Deputy Director of the Division of Biomedical Physics in the Center for Devices and Radiological Health, she guided a multidisciplinary team in creating innovative regulatory science tools that addressed critical challenges in medical device safety and effectiveness. Her leadership was instrumental in developing methods and resources for fields such as cardiology, neurostimulation, ophthalmology, in-vivo diagnostics, and advanced patient monitoring. Currently serving as Associate Director for the Division of Applied Regulatory Science in the Office of Clinical Pharmacology, she oversees research, scientific consultations, and regulatory reviews that support the FDA’s translational science priorities. Through these roles, she has combined her technical expertise with strategic vision, ensuring that scientific advancements translate into practical regulatory applications that safeguard patient health and promote medical innovation.

Research Focus

Dr. Blinova’s research focuses on advancing translational and regulatory science to accelerate the safe and effective delivery of medical products to patients. Her early work in cardiac electrophysiology and metabolism provided insights into fundamental mechanisms of heart function, laying the groundwork for her later contributions in biomedical physics and device evaluation. At the FDA, she has led research efforts that integrate computational modeling, experimental studies, and regulatory tool development to address complex safety and efficacy challenges in medical devices and drug-device combinations. Her team has developed innovative approaches to evaluate technologies in cardiology, neurostimulation, electrical safety, diagnostics, and patient monitoring, ensuring that regulatory science keeps pace with rapid technological advances. By bridging basic science, applied research, and policy, her work exemplifies the role of regulatory science in translating innovation into tangible benefits for patients and healthcare systems, while maintaining a focus on safety, effectiveness, and public health impact.

Award and Honor

Throughout her career, Dr. Blinova has been recognized for her leadership, innovation, and contributions to regulatory science. Her accomplishments include guiding the development of over forty regulatory tools that have had a lasting impact on how medical devices are assessed for safety and effectiveness. These achievements reflect not only her scientific expertise but also her ability to collaborate across disciplines to solve pressing healthcare challenges. Her recognition within the FDA and broader scientific community underscores her role as a leader who consistently advances the field of translational science. Honors and awards in her career highlight her success in bridging science and regulation, her dedication to patient safety, and her influence in shaping modern approaches to medical product evaluation. These distinctions serve as a testament to her sustained contributions, her commitment to innovation, and her growing impact as a respected figure in regulatory and biomedical research.

Publication Top Notes

  • Title: Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential
    Authors: M. Iveth Garcia, Bhavya Bhardwaj, Keri Dame, Verena Charwat, Brian A. Siemons, Ishan Goswami, Omnia A. Ismaiel, Sabyasachy Mistry, Tromondae K. Feaster, Kevin E. Healy, et al.
    Year: 2025

  • Title: In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum
    Authors: Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae Feaster, Ksenia Blinova
    Year: 2024
    Citations: 2

  • Title: Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues
    Authors: Tromondae K. Feaster, Jourdan K. Ewoldt, Anna Avila, Maura Casciola, Akshay Narkar, Christopher S. Chen, Ksenia Blinova
    Year: 2024

  • Title: Comprehensive Collection of Current Methods for Contractility and Electrophysiology Recordings in Human Cardiac Cells
    Authors: Ksenia Blinova, J. Pierson, A. Narkar
    Year: 2023

  • Title: Human in vitro assay for irreversible electroporation cardiac ablation
    Authors: Maura Casciola, Tromondae K. Feaster, M. J. Caiola, D. Keck, Ksenia Blinova
    Year: 2023

  • Title: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models
    Authors: Tromondae K. Feaster, N. Feric, I. Pallotta, A. Narkar, M. Casciola, M. P. Graziano, R. Aschar-Sobbi, Ksenia Blinova
    Year: 2022

  • Title: Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2022

  • Title: Human in vitro neurocardiac coculture (iv NCC) assay development for evaluating cardiac contractility modulation
    Authors: Akshay Narkar, Tromondae K. Feaster, Maura Casciola, Ksenia Blinova
    Year: 2022

  • Title: Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells
    Authors: Maura Casciola, Devin Keck, Tromondae K. Feaster, Ksenia Blinova
    Year: 2022

  • Title: Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
    Authors: Akshay Narkar, James M. Willard, Ksenia Blinova
    Year: 2022

  • Title: Cardiovascular medical devices: Regulatory science research overview in the office of science and engineering laboratories (OSEL) at the food and drug administration (FDA)
    Authors: K. Aycock, Ksenia Blinova, M. Casciola, B. Craven, M. Di Prima, G. D’Souza, N. Duraiswamy, M. Farahmand, P. Hariharan, L. Herbertson, et al.
    Year: 2021

  • Title: Acute effects of cardiac contractility modulation on human induced pluripotent stem cell–derived cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2021

Conclusion

Dr. Ksenia Blinova has demonstrated exceptional expertise and leadership in translational and regulatory science, particularly in the evaluation and development of cardiac therapies and medical devices. Her extensive body of research, including numerous high-impact publications on human in vitro cardiac models, contractility modulation, and electroporation assays, reflects a consistent focus on innovative approaches that bridge fundamental science with practical clinical and regulatory applications. She has led multidisciplinary teams to develop tools and methodologies that enhance patient safety, accelerate medical innovation, and provide reliable scientific evidence for regulatory decisions. Her work not only advances the understanding of cardiac electrophysiology and device performance but also sets new standards for predictive, nonclinical cardiac research. Overall, Dr. Blinova’s contributions exemplify the qualities of a pioneering researcher whose scientific rigor, leadership, and commitment to public health make her highly deserving of recognition in any Best Researcher Award.

Lichun Zhao | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Prof. Dr. Lichun Zhao | Pharmacology | Best Researcher Award

Guizhou University of Traditional Chinese Medicine, China

Prof. Dr. Lichun Zhao is a distinguished researcher and academic leader specializing in trace elements, traditional medicine, and health development. He serves as a doctoral supervisor, director of research centers and laboratories, and executive editor in chief of Trace Elements and Health Research, while holding key leadership roles in national and regional scientific associations. Recognized with numerous prestigious honors, he has successfully led major national and international projects, secured innovative medicine approvals, and contributed to product development. His prolific output includes over two hundred publications, highly cited SCI papers, multiple monographs, patents, and software copyrights, reflecting both scientific innovation and practical application. He has also been honored with multiple science and technology awards, underscoring the impact of his research. Committed to advancing both scholarship and healthcare, Prof. Zhao exemplifies excellence in integrating academic research, innovation, and leadership, making him a highly influential figure in his field.

Professional Profile 

Scopus Profile

Education

Prof. Dr. Lichun Zhao earned his Ph.D. in a field closely related to trace elements, medicine, and health sciences, building a solid academic foundation for his future research. Following his doctoral studies, he pursued postdoctoral training at Hong Kong Baptist University, where he broadened his expertise and gained valuable international research exposure. His educational journey reflects a strong emphasis on both traditional medicine and modern scientific approaches, allowing him to bridge classical knowledge with contemporary methodologies. By combining advanced laboratory techniques with deep understanding of traditional Chinese medicine, he has cultivated a unique academic profile that continues to drive his research innovations. His educational background not only prepared him for his roles in academia and research but also established his credentials as a mentor for doctoral students and an authoritative voice in integrating traditional practices with modern scientific frameworks.

Experience

Prof. Dr. Zhao has accumulated extensive academic and professional experience through his multiple leadership roles and active engagement in research. He serves as a doctoral supervisor, guiding and mentoring the next generation of researchers, while simultaneously holding positions as director of the Research Department and the Center for Trace Elements and Health Development at Guizhou University of Chinese Medicine. Beyond his university roles, he directs major laboratories in Guizhou and Guangxi, leading innovation in endangered medicinal resources. His editorial work as executive editor in chief of Trace Elements and Health Research further demonstrates his commitment to advancing scholarly communication. In addition, he actively contributes to national scientific development as a project evaluation expert for significant research foundations and technology awards. Through these experiences, Prof. Zhao has built a career that integrates research, leadership, and service, positioning him as both a pioneering scientist and an influential academic administrator.

Research Focus

The core of Prof. Dr. Zhao’s research lies in the intersection of trace elements, traditional Chinese medicine, and health development. His work emphasizes the exploration of medicinal resources, the development of innovative treatments, and the application of modern scientific tools such as big data and artificial intelligence to healthcare research. He has led numerous national and international projects aimed at advancing understanding of trace elements in human health, as well as developing standardized, evidence-based approaches to traditional medicine. A significant part of his focus is dedicated to the preservation and innovation of endangered medicinal materials, ensuring sustainable resources for future therapeutic use. His achievements include obtaining clinical approvals for new medicine, producing certified products, and publishing influential studies recognized globally. Prof. Zhao’s research is notable for its ability to combine ancient knowledge with modern technology, creating novel solutions that enhance healthcare outcomes and scientific advancement.

Award and Honor

Prof. Dr. Zhao has been widely recognized for his scientific excellence and leadership with numerous national and regional awards. He was the first to receive the prestigious National Youth Qihuang Scholar distinction and has been selected for Hong Kong’s “Excellent Talent Plan.” His honors include recognition as an Outstanding Scholar in Guangxi, a leader of high-level innovation teams, and a candidate in talent development initiatives such as the “Ten Hundred Thousand Talents Project.” He has also received the Guangxi Youth Science and Technology Award and multiple provincial science and technology prizes, including the Guangxi Science and Technology Progress Award and the Jilin Province Natural Science Award. His contributions have further been acknowledged through the China Industry-University-Research Cooperation Innovation Award. Collectively, these distinctions highlight not only his research excellence but also his role as an innovator and leader whose work has had profound impact in both academic and applied scientific fields.

Publications Top Notes

  • Title: The close relationship between trace elements (Cu, Fe, Zn, Se, Rb, Si, Cr, and V) and Alzheimer’s disease: Research progress and insights
    Authors: Zhao Lichun et al.
    Year: 2025

  • Title: Bacteriostatic activity and mechanism of minerals containing rubidium
    Authors: Zhao Lichun et al.
    Year: 2025

  • Title: Traditional Chinese medicine in chronic rhinosinusitis: Mechanisms and postoperative recovery
    Authors: Zhao Lichun et al.
    Year: 2025
    Citations: 3

  • Title: Rosmarinic acid promotes mitochondrial fission and induces ferroptosis in triple-negative breast cancer cells
    Authors: Zhao Lichun et al.
    Year: 2025
    Citations: 13

  • Title: Interfacial Stabilization through MOF-Polymer Core-Shell Design: Ultraefficient, Stable and Recyclable Enzymatic Microreactors
    Authors: Zhao Lichun et al.
    Year: 2025

  • Title: Rubidium salt can effectively relieve the symptoms of DSS-induced ulcerative colitis
    Authors: Zhao Lichun et al.
    Year: 2024
    Citations: 22

Conclusion

The reviewed publications of Prof. Dr. Lichun Zhao reflect a strong and diverse research portfolio spanning trace elements, traditional Chinese medicine, cancer biology, inflammatory diseases, and innovative material science applications. His works demonstrate both depth in exploring mechanisms of disease and breadth in applying interdisciplinary approaches to health solutions. The range of topics covered—from Alzheimer’s disease and rhinosinusitis to breast cancer and ulcerative colitis—highlights his ability to integrate traditional medicine knowledge with modern biomedical and technological advances. The citations already received for some of these recent studies, particularly in high-impact areas such as cancer research and therapeutic innovations, indicate growing recognition of his contributions within the scientific community. Overall, his research achievements showcase academic rigor, innovation, and practical significance, further strengthening his candidacy for recognition through prestigious research awards.

Dr. Christian Seebauer | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Christian Seebauer | Pharmacology | Best Researcher Award

Senior Consultant at Department of Oral and Maxillofacial Surgery / Plastic surgery, University Medicine Lübeck, Germany

Dr. med. Christian Seebauer, MD, DDS, is a distinguished clinician-scientist with dual qualifications in medicine and dentistry and board certifications in Oral and Maxillofacial Surgery and Oral Surgery. Currently a Senior Consultant at University Medical Center Lübeck, he has held several leadership roles in academic surgery. His research focuses on innovative therapies such as cold atmospheric plasma for cancer, wound healing, and oral diseases. He has authored impactful publications in high-ranking journals, with a strong emphasis on translational and interdisciplinary research. Awarded a summa cum laude for his medical doctorate, he is pursuing a second doctorate in dental medicine and a habilitation. Dr. Seebauer is actively involved in clinical trials, academic teaching, and scientific advising. His work reflects a commitment to advancing patient care through science, collaboration, and clinical excellence, making him a highly suitable candidate for prestigious research recognition such as the Best Researcher Award.

Professional Profile 

Google Scholar
Scopus Profile

Education

Dr. Christian Seebauer’s educational background reflects his exceptional commitment to interdisciplinary medical science. He earned his medical degree from Friedrich-Schiller-University Jena in 2006, graduating with high distinction and obtaining his medical license with a “very good” grade. Driven by an interest in craniofacial care, he pursued a second degree in dentistry at Ernst-Moritz-Arndt-University Greifswald, earning his dental license in 2015, again with top marks. He completed specialist training in Oral and Maxillofacial Surgery (2020) and Oral Surgery (2021), and is on track to receive an additional qualification in Plastic and Aesthetic Surgery by 2025. Academically, he achieved his Doctor of Medicine (summa cum laude) from Charité – Berlin in 2012, is completing a second doctorate in dental medicine, and is preparing his habilitation at University Medical Center Lübeck. His dual training uniquely equips him for complex surgical, academic, and translational roles in modern healthcare.

Professional Experience

Dr. Seebauer has accumulated extensive clinical and academic experience in leading German medical institutions. He began his residency in musculoskeletal surgery at Charité – Berlin (2007–2010), then transitioned into Oral and Maxillofacial Surgery at University Medical Centers in Jena and Greifswald. At Greifswald, he steadily advanced from resident to Specialist, then Senior Consultant, and eventually Managing Senior Consultant by 2023. In August 2024, he was appointed Senior Consultant at the University Medical Center Lübeck. Throughout his career, he has taken on multiple responsibilities beyond patient care, including roles in transfusion medicine, radiation safety, and medical coding. Dr. Seebauer is experienced in running clinical trials, mentoring young surgeons, and integrating advanced surgical techniques such as microvascular tissue transfer and plasma-based therapies. His professional trajectory demonstrates continuous growth in clinical leadership, academic excellence, and institutional trust, confirming his status as a respected authority in surgical and translational medicine.

Research Interest

Dr. Seebauer’s research centers on innovative, translational approaches to oral, mucosal, and dermal disease management, with a particular emphasis on cold atmospheric plasma. His work spans a range of high-impact medical themes, including wound healing, cancer therapy, precancerous lesions, chronic inflammation, and alternative cancer treatments. He has contributed significantly to both preclinical and clinical investigations, exploring how plasma technologies can improve outcomes in head and neck cancer, oral lichen planus, and leukoplakia. His recent studies include cohort analyses on the effects of anticoagulants on wound healing and the global impact of HPV vaccination on malignancy risks. He is actively involved in the planning of prospective, multicenter clinical trials and collaborates internationally via networks like TriNetX. His multidisciplinary approach combines surgery, oncology, immunology, and biomedical engineering, showcasing his ability to merge clinical insight with experimental innovation. These interests place him at the forefront of translational medical research in Europe.

Award and Honor

Dr. Christian Seebauer has earned several distinctions throughout his academic and clinical career. He was awarded his Doctor of Medicine degree summa cum laude, one of the highest academic honors in Germany, by the prestigious Charité – University Medical Center Berlin. His scientific work has been published in internationally renowned, peer-reviewed journals such as Radiology, Oral Diseases, and Pharmacological Research, some with impact factors exceeding 10. He has held trusted leadership roles, including Managing Senior Consultant, and serves as a Scientific Advisor to neoplas MED. His selection for these positions reflects institutional recognition of his scientific and clinical integrity. Although not explicitly listed, his rising trajectory in academic medicine and involvement in high-level research projects suggest a strong reputation within professional circles. His affiliations with organizations such as the National Center for Plasma Medicine and Rotary Club also highlight his commitment to service and excellence beyond his clinical duties.

Conclusion

Dr. Christian Seebauer exemplifies the ideal candidate for recognition as a Best Researcher. With dual qualifications in medicine and dentistry, a track record of clinical leadership, and a deep commitment to translational research, he bridges the gap between scientific discovery and patient care. His pioneering work in cold atmospheric plasma and its applications in oncology and regenerative medicine is both innovative and impactful, reflecting future-forward thinking in clinical science. His publication record, leadership roles, and collaborative involvement in global research initiatives further establish his credibility and influence in the medical community. Dr. Seebauer’s academic path—marked by excellence, versatility, and continual advancement—underscores his dedication to improving healthcare through research, education, and clinical innovation. As he continues his habilitation and leads new clinical trials, his contributions are poised to shape future standards in surgery and therapeutic technology. He is highly deserving of prestigious accolades such as the Best Researcher Award.

Publications Top Notes

  • Title: Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer

    • Authors: HR Metelmann, C Seebauer, V Miller, A Fridman, G Bauer, DB Graves, …

    • Year: 2018

    • Citations: 353

  • Title: Head and neck cancer treatment and physical plasma

    • Authors: HR Metelmann, DS Nedrelow, C Seebauer, M Schuster, T von Woedtke, …

    • Year: 2015

    • Citations: 256

  • Title: Molecular mechanisms of the efficacy of cold atmospheric pressure plasma (CAP) in cancer treatment

    • Authors: ML Semmler, S Bekeschus, M Schäfer, T Bernhardt, T Fischer, K Witzke, …

    • Year: 2020

    • Citations: 216

  • Title: Comprehensive clinical plasma medicine: cold physical plasma for medical application

    • Authors: HR Metelmann, T Von Woedtke, KD Weltmann

    • Year: 2018

    • Citations: 162

  • Title: Visible tumor surface response to physical plasma and apoptotic cell kill in head and neck cancer

    • Authors: M Schuster, C Seebauer, R Rutkowski, A Hauschild, F Podmelle, …

    • Year: 2016

    • Citations: 152

  • Title: Cold atmospheric pressure plasma in wound healing and cancer treatment

    • Authors: L Boeckmann, M Schäfer, T Bernhardt, ML Semmler, O Jung, G Ojak, …

    • Year: 2020

    • Citations: 100

  • Title: Treating cancer with cold physical plasma: On the way to evidence‐based medicine

    • Authors: HR Metelmann, C Seebauer, R Rutkowski, M Schuster, S Bekeschus, …

    • Year: 2018

    • Citations: 65

  • Title: Hyperspectral imaging for in vivo monitoring of cold atmospheric plasma effects on microcirculation in treatment of head and neck cancer and wound healing

    • Authors: R Rutkowski, M Schuster, J Unger, C Seebauer, HR Metelmann, …

    • Year: 2017

    • Citations: 58

  • Title: Ankle laxity: stress investigation under MRI control

    • Authors: CJ Seebauer, HJ Bail, JC Rump, B Hamm, T Walter, UKM Teichgräber

    • Year: 2013

    • Citations: 55

  • Title: Side effects in cold plasma treatment of advanced oral cancer—Clinical data and biological interpretation

    • Authors: M Schuster, R Rutkowski, A Hauschild, RK Shojaei, T von Woedtke, …

    • Year: 2018

    • Citations: 48

  • Title: Physical plasma and leukocytes–immune or reactive?

    • Authors: S Bekeschus, C Seebauer, K Wende, A Schmidt

    • Year: 2018

    • Citations: 42

  • Title: Plasmamedizin

    • Authors: HR Metelmann, T von Woedtke, KD Weltmann

    • Year: 2016

    • Citations: 42

  • Title: Cold argon plasma as adjuvant tumour therapy on progressive head and neck cancer: A preclinical study

    • Authors: S Hasse, C Seebauer, K Wende, A Schmidt, HR Metelmann, …

    • Year: 2019

    • Citations: 41

  • Title: Third molars and periodontal damage of second molars in the general population

    • Authors: S Kindler, B Holtfreter, T Koppe, M Mksoud, C Lucas, C Seebauer, …

    • Year: 2018

    • Citations: 36

  • Title: Plasma-derived reactive species shape a differentiation profile in human monocytes

    • Authors: E Freund, J Moritz, M Stope, C Seebauer, A Schmidt, S Bekeschus

    • Year: 2019

    • Citations: 34

Angelica Rachel Carpio | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Ms. Angelica Rachel Carpio | Pharmacology | Best Researcher Award

Ms. Angelica Rachel Carpio at DLSU Laguna, Philippines

Angelica Rachel E. Carpio is a highly driven bioengineer and nanotechnology researcher from Mapúa University, where she is completing both her Bachelor’s and Master’s degrees in Biological Engineering. With published research in respected journals such as Life and the Journal of the Taiwan Institute of Chemical Engineers, her work explores innovative applications of natural compounds and nanomaterials for therapeutic use. She has hands-on experience in advanced laboratory techniques, computational modeling, and scientific writing, strengthened by international research training in Taiwan and immersion in Japan. Currently, she contributes to nanotechnology development at De La Salle University, focusing on photoluminescent inks using carbon nanodots. In addition to her technical expertise, Angelica has held leadership roles in various academic organizations, showcasing her teamwork and communication skills. Her multidisciplinary approach, academic excellence, and commitment to scientific advancement make her a promising and impactful researcher in the field of bioengineering and nanotechnology.

Professional Profile 

Scopus Profile

Education

Angelica Rachel E. Carpio is currently pursuing a dual degree program—Bachelor and Master of Science in Biological Engineering—at Mapúa University in Manila, Philippines, from 2020 to 2025. Her academic journey reflects consistent excellence, having previously completed the Science, Technology, Engineering, and Mathematics (STEM) strand during her senior high school years at the same university. Throughout her education, Angelica has been recognized for her academic performance, earning quarterly and semestral honors. Her foundational years at St. Mary’s Academy of Caloocan City also demonstrate early academic strength. Her coursework blends bioengineering, nanotechnology, and computational sciences, preparing her for interdisciplinary research. Her involvement in technical and laboratory-intensive education has equipped her with both theoretical knowledge and practical skills, making her a well-rounded scholar capable of tackling complex scientific challenges across engineering and life sciences.

Professional Experience

Angelica Rachel E. Carpio has gained practical research and academic experience in multiple capacities across institutions. As of March 2025, she serves as a Project Technical Assistant I at De La Salle University’s Center for Natural Sciences and Environmental Research, where she is actively involved in nanotechnology research, particularly the development of photoluminescent inks using carbon nanodots. Previously, she completed a research internship at National I-lan University in Taiwan, contributing to projects in biochemistry and microbial fuel cells, which culminated in a scholarly publication. Her earlier experience includes a role as a Student Assistant at Mapúa University, where she facilitated administrative tasks and student outreach. She also participated in a scientific immersion program in Tokyo, Japan, expanding her global perspective. These diverse roles reflect a well-rounded professional background that combines scientific inquiry, technical execution, and organizational support, laying a strong foundation for a research-intensive career.

Research Interest

Angelica’s research interests are rooted in the intersection of bioengineering, nanotechnology, and computational biology. She focuses on developing therapeutic strategies using natural products, such as plant metabolites and microbial fermentation, combined with modern molecular techniques. Her recent publications explore the anti-cancer potential of Vaccinium-derived compounds and the enhanced production of anthraquinones in rhubarb through fermentation, showcasing her inclination toward pharmacological innovation using bioinformatics tools like molecular docking and network analysis. She is also engaged in nanomaterial research, particularly in developing carbon-based nanodots for photoluminescent applications, revealing a keen interest in functional biomaterials. Her ability to integrate wet-lab experiments with computational modeling highlights a strong systems-level approach to research. This multidimensional interest positions her at the forefront of modern biological engineering, where she aims to bridge natural sciences with engineered solutions for health and environmental applications.

Award and Honor

Angelica Rachel Carpio has consistently earned recognition for her academic and leadership excellence throughout her educational journey. She has received quarterly and semestral academic excellence awards during her time in senior high school at Mapúa University, where she graduated with honors. At St. Mary’s Academy of Caloocan City, she was also an Academic Excellence Awardee, underscoring her consistent performance from an early age. While specific research awards are not listed, her publications in reputable international journals, her international research internship in Taiwan, and participation in a scientific immersion in Japan stand as strong indicators of merit. Furthermore, her selection as a Project Technical Assistant I at a prominent research center such as De La Salle University is, in itself, a form of professional recognition. These accomplishments reflect both academic rigor and early research impact, validating her potential as a high-achieving scholar and future leader in scientific research.

Conclusion

Angelica Rachel E. Carpio emerges as a promising and multifaceted researcher with a solid educational background, hands-on professional experience, and a clear focus on innovation at the intersection of nanotechnology and biological engineering. Her early contributions to research through published work, international exposure, and technical roles at prestigious institutions showcase her ability to apply scientific knowledge to real-world problems. Angelica’s diverse skill set—from laboratory techniques and computational modeling to leadership in academic organizations—demonstrates maturity beyond her years. She represents the new generation of researchers who are collaborative, globally aware, and technically adept. With continued mentorship and opportunities to expand her research portfolio, Angelica is well on track to make meaningful contributions to the scientific community. Her credentials make her an excellent candidate for honors such as the Best Researcher Award, especially in the category of emerging or early-career researchers.

Publications Top Notes

  • Title: Berries as Nature’s Therapeutics: Exploring the Potential of Vaccinium Metabolites in Gastric Cancer Treatment Through Computational Insights
    Authors: Carpio, Angelica Rachel; Talubo, Nicholas Dale D.; Tsai, Po Wei; Chen, Boryann; Tayo, Lemmuel Lara
    Year: 2025
    Journal: Life

Franciska Erdő | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on by World Top Scientists

Prof. Dr. Franciska Erdő | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

full professor at Pázmány Péter Catholic University, Hungary

Franciska Vidáné Dr. Erdő is a distinguished researcher and professor in drug research and development, with extensive experience in academia and the pharmaceutical industry. Born on May 28, 1964, in Budapest, Hungary, she has contributed significantly to pharmacology, drug delivery, and biomedical research. Over her career, she has held leadership roles in prestigious institutions across Hungary, Germany, and France. As a full professor and lab head at Pázmány Péter Catholic University, she plays a key role in advancing scientific knowledge. Her research has been widely recognized, earning her multiple fellowships and memberships in international scientific societies. Dr. Erdő has supervised numerous students, organized international scientific meetings, and served as a reviewer for high-impact journals. She is also actively involved in grant evaluation for major research funding agencies in Europe, further establishing her as a leading expert in her field.

Professional Profile

Education

Dr. Erdő’s academic journey is rooted in pharmaceutical sciences. She obtained her MSc in Pharmacy from Semmelweis University, Faculty of Pharmacy, in 1987 with excellent distinction. She continued her studies at the same institution, earning her University Doctor title in pharmacology in 1994, followed by a PhD in 1997, both summa cum laude. To further enhance her expertise, she pursued a habilitation at Pázmány Péter Catholic University in 2019, ultimately achieving the title of full professor in 2024. Additionally, she has undertaken specialized training, including EU grant writing and experimental animal research under new EU regulations. Her diverse educational background has enabled her to excel in drug development, pharmacology, and biotechnology, equipping her with a strong foundation to lead innovative research in these fields.

Professional Experience

Dr. Erdő’s professional career spans more than three decades, encompassing roles in academia, research institutes, and the pharmaceutical industry. She has held various research fellow and senior research fellow positions in leading institutions such as Sanofi-Synthelabo Chinoin, IVAX Drug Research Institute, and SOLVO Biotechnology. Between 2000 and 2003, she was a Max Planck Fellow at the Max-Planck Institute in Germany, furthering her expertise in neurological research. She has also worked as a scientific researcher at Charité Medical University in Berlin. Since 2014, she has been an integral part of Pázmány Péter Catholic University, where she has progressed from senior research fellow to full professor and lab head. Her leadership in drug research and development, coupled with her extensive collaborations with international institutions, has significantly contributed to the advancement of pharmaceutical sciences.

Research Interests

Dr. Erdő’s research focuses on drug delivery across physiological barriers, including the skin, blood-brain barrier, and mucosal tissues. Her studies explore transdermal and intranasal drug administration, pharmacokinetics, and tissue engineering. She has contributed to the development of lab-on-a-chip models for drug testing, providing innovative solutions for pharmaceutical research. Her interdisciplinary approach combines pharmacology, biomedical engineering, and nanotechnology to improve drug formulation and delivery methods. She has authored numerous high-impact publications on skin permeability, microfluidic diffusion chambers, and age-related changes in drug absorption. Her research also includes in vitro and ex vivo studies on skin-on-a-chip platforms, contributing to advancements in personalized medicine. Dr. Erdő’s work has gained international recognition, shaping the future of drug development and targeted therapy solutions.

Awards and Honors

Dr. Erdő has been the recipient of numerous prestigious awards and fellowships throughout her career. She was a Max Planck Fellow from 2000 to 2003, a Charité Medical University Scholar in 2006, and a recipient of the LE STUDIUM Fellowship in 2022 under the Smart Loire Valley program in France. Her excellence in teaching and research has been recognized through multiple Teaching-Research Excellence Scholarships at Pázmány Péter Catholic University. She has also received publication fellowships for her outstanding contributions to scientific literature. Additionally, she plays a crucial role as a grant evaluator for the EU’s Horizon programs, the Austrian Science Fund, and other major research funding agencies. Her achievements highlight her significant impact on the global scientific community, reinforcing her reputation as a leading expert in pharmaceutical and biomedical research.

Conclusion

Dr. Franciska Vidáné Erdő is a highly suitable candidate for the Best Researcher Award due to her outstanding contributions to drug research, mentorship, and international collaborations. Her extensive publication record, leadership in scientific organizations, and impact on pharmacology and biomedical sciences make her a strong contender. Enhancing industry engagement and public science communication could further solidify her position as a top researcher.

Publications Top Noted

1. In Vitro Functional and Structural Evaluation of Low-Complexity Artificial Human Epidermis for 3D Tissue Engineering

  • Author: Erdő F., et al.
  • Year: 2025
  • Journal: Bioengineering
  • DOI: 10.3390/bioengineering12030230

2. Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study

3. Progress in Topical and Transdermal Drug Delivery Research—Focus on Nanoformulations

4. Mathematical Modeling of Transdermal Delivery of Topical Drug Formulations in a Dynamic Microfluidic Diffusion Chamber in Health and Disease

5. Rodent Models of Dermatological Disorders

6. Models for Barrier Understanding in Health and Disease in Lab-on-a-Chips

7. Transdermal Delivery of α-Aminophosphonates as Semisolid Formulations—An In Vitro-Ex Vivo Study

8. Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)-In Vitro Testing

9. Editorial: Women in Drug Metabolism and Transport: 2021

10. Structural and Functional Analysis of Excised Skins and Human Reconstructed Epidermis with Confocal Raman Spectroscopy and in Microfluidic Diffusion Chambers

11. Novel Aspects of Raman Spectroscopy in Skin Research

  • Author: Erdő F., et al.
  • Year: 2022
  • Journal: Experimental Dermatology
  • DOI: 10.1111/exd.14645

12. Characterization and Ex Vivo Evaluation of Excised Skin Samples as Substitutes for Human Dermal Barrier in Pharmaceutical and Dermatological Studies

  • Author: Erdő F., et al.
  • Year: 2022
  • Journal: Skin Research and Technology
  • DOI: 10.1111/srt.13165

13. Drug Delivery through the Psoriatic Epidermal Barrier—A “Skin-On-A-Chip” Permeability Study and Ex Vivo Optical Imaging

  • Author: Erdő F., et al.
  • Year: 2022
  • Journal: International Journal of Molecular Sciences
  • DOI: 10.3390/ijms23084237

14. Skin-on-a-Chip Technology for Testing Transdermal Drug Delivery—Starting Points and Recent Developments

15. Age-Related Inflammatory Balance Shift, Nasal Barrier Function, and Cerebro-Morphological Status in Healthy and Diseased Rodents